Skip to content

Enhanced Recovery After Surgery(ERAS) for Gastric Cancer and Perioperative Nutritional Status

The Effect of Perioperative Nutritional Status on Enhanced Recovery After Surgery for Gastric Cancer

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03043183
Enrollment
1400
Registered
2017-02-03
Start date
2017-03-01
Completion date
2021-09-30
Last updated
2017-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nutrition Disorders

Keywords

gastric cancer, Enhanced recovery after surgery

Brief summary

This study is a prospective, single-center, randomized controlled trial. The study protocol was approved by the Ethics Committee at the First Hospital of Jilin University.The perioperation nutritional status will be assessed in gastric cancer patients within ERAS protocols.The ERAS patients were randomly divided into perioperational nutrition support group and conventional pathway group . Inter-group differences were evaluated for nutritional index,clinical recovery index, complications etc.

Interventions

PROCEDUREperioperational nutrition surpport

Oral enteral nutrition support(25 kcal/kg or 1.5 g protein/kg) for 3 days before operation

Sponsors

The First Hospital of Jilin University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* A preoperative cancer stage of T2, T3, T4, Any N, M0 without digestive obstruction confirmed by whole body CT scan, which could be treated with laparoscopic gastrectomy; * age 18-75 years; * pathologic confirmation of gastric adenocarcinoma by endoscopic biopsy; * normal hematological, renal, hepatic, and cardiac parameters,American Society of Anesthesiology (ASA) score \< III without severe systemic disease; * no history of treatment with neoadjuvant chemotherapy and/or radiotherapy * PG-SGA score ≥2,\<9

Exclusion criteria

* patients requiring conversion to open gastrectomy * excessive bleeding (˃ 500 mL);and patients opting out of the study.

Design outcomes

Primary

MeasureTime frameDescription
complication30 days after operationfever;wound infection;post-operation bleeding;ileus;stenosis;leakage

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026